Cancer Therapy

Monoclonal Antibodies, Lymphokines New Developments in Surgical Oncology and Chemo- and Hormonal Therapy

  • Hans G. Beger
  • Markus Büchler
  • Ralph A. Reisfeld
  • Gregor Schulz

Table of contents

  1. Front Matter
    Pages I-XII
  2. Monoclonal Antibodies

    1. Front Matter
      Pages 1-1
    2. R. A. Reisfeld, B. Muller, H.-M. Yang
      Pages 3-9
    3. A. Planting, J. Verweij, P. Cox, M. Pillay, G. Stoter
      Pages 27-31
    4. M. Büchler, R. Kübel, R. Klapdor, K.-H. Muhrer, H. Friess, B. Lorenz et al.
      Pages 32-41
    5. H. Mellstedt, J.-E. Frödin, G. Masucci, C. Lindemalm, C. Wedelin, B. Christensson et al.
      Pages 42-50
    6. W. G. Dippold, K.-H. Meyer zum Büschenfelde
      Pages 51-55
  3. Lymphokines

    1. Front Matter
      Pages 71-71
    2. A. Lindemann, F. Herrmann, H. Gamm, W. Oster, R. Mertelsmann
      Pages 73-84
    3. R. G. Steis, J. Clark, D. L. Longo, J. Smith, R. Miller, F. Ruscetti et al.
      Pages 103-111
    4. F. Porzsolt, W. Digel, C. Buck, A. Raghavachar, M. Stefanic, W. Schöniger
      Pages 124-131
  4. New Approaches in Surgical Oncology

    1. Front Matter
      Pages 141-141
    2. R. Bittner, H. G. Beger
      Pages 143-153
    3. K.-H. Schultheis, M. Pliess, H.-H. Gentsch, H. Bödeker, C. Gebhardt, K. Schwemmle
      Pages 201-215
  5. Chemotherapy and Hormonal Therapy

  6. Back Matter
    Pages 303-308

About these proceedings


A variety of new cancer therapy modalities are discussed and evaluated in this book. It aims to demonstrate that the combination of classical chemo- and radiotherapy with new approaches in the field of immunotherapy can result in an improved treatment modality. Immunotherapy in this context consists of therapy with monoclonal antibodies, hematopoietic growth factors and other lymphokines. Results of early clinical trials with IL-2, GM-CSF and monoclonal antibodies against gastrointestinal tumors and melanoma are included. The progress in regional chemotherapy strategies, for example of the liver, is shown. In addition, the development of new chemotherapeutic agents with a different mode of action as well as better tolerability is presented. The use of hormones, such as LH-RH agonists, allows hormone-dependent tumors such as prostatic and breast cancer to be treated without strong adverse reactions. These recent findings give the reader insight into exciting therapeutic directions made possible by such combined, rather than single, modalities.


breast cancer cancer cancer therapy chemotherapy clinical trial hormones immunotherapy liver melanoma radiotherapy

Editors and affiliations

  • Hans G. Beger
    • 1
  • Markus Büchler
    • 1
  • Ralph A. Reisfeld
    • 2
  • Gregor Schulz
    • 3
  1. 1.Department of General SurgeryUniversity of UlmUlmGermany
  2. 2.Division of Tumor Cell BiologyScripps Clinic & Research FoundationLa JollaUSA
  3. 3.Clinical ResearchBehringwerke AG MarburgMarburgGermany

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 1989
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-73723-7
  • Online ISBN 978-3-642-73721-3
  • Buy this book on publisher's site